Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines

BMC Medical Genomics

Volumn 4, Issue , 2011, Pages

  Ha, Kevin C H ^a   Lalonde, Emilie ^a   Li, Lili ^a,b   Cavallone, Luca ^a,b   Natrajan, Rachael ^c   Lambros, Maryou B ^c   Mitsopoulos, Costas ^c   Hakas, Jarle ^c   Kozarewa, Iwanka ^c   Fenwick, Kerry ^c   Lord, Chris J ^c   Ashworth, Alan ^c   Vincent Salomon, Anne ^d   Basik, Mark ^b,e   Reis Filho, Jorge S ^c   Majewski, Jacek ^a   Foulkes, William D ^a,b,e  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d INSTITUT CURIE   (France)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTOME; BRCA1 PROTEIN; MESSENGER RNA;

ADNP C20ORF132 GENE; ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER CELL; CHROMOSOME BREAKAGE; CONTROLLED STUDY; COPY NUMBER VARIATION; FUSION GENE; GENE EXPRESSION PROFILING; GENE FUSION; GENE MUTATION; GENE OVEREXPRESSION; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; ONCOGENE; PRIORITY JOURNAL; REGULATORY SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; WWC1 ADRBK2 GENE; BREAST TUMOR; FEASIBILITY STUDY; FEMALE; GENETICS; METHODOLOGY; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; SEQUENCE ANALYSIS; TUMOR CELL LINE;

BASE SEQUENCE; BRCA1 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMOSOME BREAKPOINTS; DNA COPY NUMBER VARIATIONS; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE FUSION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; RNA, MESSENGER; SEQUENCE ANALYSIS, RNA;

EID: 80054915820     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-4-75     Document Type: Article

References (58)

1. The impact of translocations and gene fusions on cancer causation. Mitelman F, Johansson B, Mertens F, Nat Rev Cancer 2007 7 233 245 10.1038/nrc2091 17361217 (Pubitemid 46480968)
2. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Shtivelman E, Lifshitz B, Gale RP, Canaani E, Nature 1985 315 550 554 10.1038/315550a0 2989692 (Pubitemid 15021190)
3. Transcriptome sequencing to detect gene fusions in cancer. Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X, Sam L, Barrette T, Palanisamy N, Chinnaiyan AM, Nature 2009 458 97 101 10.1038/nature07638 19136943
4. Chimeric transcript discovery by paired-end transcriptome sequencing. Maher CA, Palanisamy N, Brenner JC, Cao X, Kalyana-Sundaram S, Luo S, Khrebtukova I, Barrette TR, Grasso C, Yu J, et al. Proc Natl Acad Sci USA 2009 106 12353 12358 10.1073/pnas.0904720106 19592507
5. Integrative analysis of the melanoma transcriptome. Berger MF, Levin JZ, Vijayendran K, Sivachenko A, Adiconis X, Maguire J, Johnson LA, Robinson J, Verhaak RG, Sougnez C, et al. Genome Res 2010 20 413 427 10.1101/gr.103697.109 20179022
6. RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Marioni J, Mason C, Mane S, Stephens M, Gilad Y, Genome Res 2008 18 1509 1517 10.1101/gr.079558.108 18550803
7. RNA-Seq: a revolutionary tool for transcriptomics. Wang Z, Gerstein M, Snyder M, Nat Rev Genet 2009 10 57 63 10.1038/nrg2484 19015660
8. Variation of breast cancer risk among BRCA1/2 carriers. Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, Langholz B, Bernstein L, Olsen JH, Lynch CF, et al. JAMA 2008 299 194 201 10.1001/jama.2007.55-a 18182601
9. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. Tai YC, Domchek S, Parmigiani G, Chen S, J Natl Cancer Inst 2007 99 1811 1814 10.1093/jnci/djm203 18042939 (Pubitemid 351767200)
10. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, et al. Am J Hum Genet 2003 72 1117 1130 10.1086/375033 12677558 (Pubitemid 36530000)
11. Molecular portraits of human breast tumours. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Nature 2000 406 747 752 10.1038/35021093 10963602
12. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Proc Natl Acad Sci USA 2001 98 10869 10874 10.1073/pnas.191367098 11553815 (Pubitemid 32878711)
13. Basal-like breast cancer: a critical review. Rakha EA, Reis-Filho JS, Ellis IO, J Clin Oncol 2008 26 2568 2581 10.1200/JCO.2007.13.1748 18487574
14. Triple negative tumours: a critical review. Reis-Filho JS, Tutt AN, Histopathology 2008 52 108 118 18171422 (Pubitemid 350265179)
15. Triple-negative breast cancer. Foulkes WD, Smith IE, Reis-Filho JS, N Engl J Med 2010 363 1938 1948 10.1056/NEJMra1001389 21067385
16. Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer. Arnes JB, Begin LR, Stefansson I, Brunet JS, Nielsen TO, Foulkes WD, Akslen LA, J Clin Pathol 2009 62 139 146 18682421
17. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, et al. Clin Cancer Res 2004 10 5367 5374 10.1158/1078-0432.CCR-04-0220 15328174 (Pubitemid 39100473)
18. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA, Becker L, Carneiro F, MacPherson N, Horsman D, et al. Cancer Cell 2002 2 367 376 10.1016/S1535-6108(02)00180-0 12450792 (Pubitemid 41039103)
19. Brca1 controls homology-directed DNA repair. Moynahan ME, Chiu JW, Koller BH, Jasin M, Mol Cell 1999 4 511 518 10.1016/S1097-2765(00)80202-6 10549283 (Pubitemid 29531131)
20. Homologous recombination in mammalian cells. Bollag RJ, Waldman AS, Liskay RM, Annu Rev Genet 1989 23 199 225 10.1146/annurev.ge.23.120189.001215 2694931 (Pubitemid 20033402)
21. BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene. Snouwaert JN, Gowen LC, Latour AM, Mohn AR, Xiao A, DiBiase L, Koller BH, Oncogene 1999 18 7900 7907 10630642 (Pubitemid 30066235)
22. Mechanism and regulation of human non-homologous DNA end-joining. Lieber MR, Ma Y, Pannicke U, Schwarz K, Nat Rev Mol Cell Biol 2003 4 712 720 10.1038/nrm1202 14506474 (Pubitemid 37082186)
23. The role of DNA breaks in genomic instability and tumorigenesis. Mills KD, Ferguson DO, Alt FW, Immunol Rev 2003 194 77 95 10.1034/j.1600-065X.2003. 00060.x 12846809 (Pubitemid 36886430)
24. Complex landscapes of somatic rearrangement in human breast cancer genomes. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edkins S, Mudie LJ, et al. Nature 2009 462 1005 1010 10.1038/nature08645 20033038
25. Fast and accurate short read alignment with Burrows-Wheeler transform. Li H, Durbin R, Bioinformatics 2009 25 1754 1760 10.1093/bioinformatics/btp324 19451168
26. The Sequence Alignment/Map format and SAMtools. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, Bioinformatics 2009 25 2078 2079 10.1093/bioinformatics/btp352 19505943
27. BLAT - the BLAST-like alignment tool. Kent WJ, Genome Res 2002 12 656 664 11932250 (Pubitemid 34308645)
28. Replacing suffix trees with enhanced suffix arrays. Abouelhoda MI, Kurtz S, Ohlebusch E, Journal of Discrete Algorithms 2004 53 86
29. BEDTools: a flexible suite of utilities for comparing genomic features. Quinlan AR, Hall IM, Bioinformatics 2010 26 841 842 10.1093/bioinformatics/ btq033 20110278
30. The UCSC Table Browser data retrieval tool. Karolchik D, Hinrichs AS, Furey TS, Roskin KM, Sugnet CW, Haussler D, Kent WJ, Nucleic Acids Res 2004 32 493 496 10.1093/nar/gkh103 14681465
31. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Mortazavi A, Williams B, McCue K, Schaeffer L, Wold B, Nat Methods 2008 5 621 628 10.1038/nmeth.1226 18516045 (Pubitemid 351911867)
32. Primer3 on the WWW for general users and for biologist programmers. Rozen S, Skaletsky H, Methods Mol Biol 2000 132 365 386 10547847
33. Challenges of sequencing human genomes. Koboldt DC, Ding L, Mardis ER, Wilson RK, Brief Bioinform 2010 11 484 498 10.1093/bib/bbq016 20519329
34. Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum. Lae M, Freneaux P, Sastre-Garau X, Chouchane O, Sigal-Zafrani B, Vincent-Salomon A, Mod Pathol 2009 22 291 298 10.1038/modpathol.2008.184 19011601
35. ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex. Li Z, Tognon CE, Godinho FJ, Yasaitis L, Hock H, Herschkowitz JI, Lannon CL, Cho E, Kim SJ, Bronson RT, et al. Cancer Cell 2007 12 542 558 10.1016/j.ccr.2007.11.012 18068631 (Pubitemid 350199073)
36. ETV6-NTRK3 - Trk-ing the primary event in human secretory breast cancer. Euhus DM, Timmons CF, Tomlinson GE, Cancer Cell 2002 2 347 348 10.1016/S1535-6108(02)00184-8 12450787 (Pubitemid 41039098)
37. Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. Christopher SA, Diegelman P, Porter CW, Kruger WD, Cancer Res 2002 62 6639 6644 12438261 (Pubitemid 35364132)
38. A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer. Schmid M, Sen M, Rosenbach MD, Carrera CJ, Friedman H, Carson DA, Oncogene 2000 19 5747 5754 10.1038/sj.onc.1203942 11126361
39. Kibra is a regulator of the Salvador/Warts/Hippo signaling network. Genevet A, Wehr MC, Brain R, Thompson BJ, Tapon N, Dev Cell 2010 18 300 308 10.1016/j.devcel.2009.12.011 20159599
40. Cloning and characterization of the human activity-dependent neuroprotective protein. Zamostiano R, Pinhasov A, Gelber E, Steingart RA, Seroussi E, Giladi E, Bassan M, Wollman Y, Eyre HJ, Mulley JC, et al. The Journal of biological chemistry 2001 276 708 714 11013255 (Pubitemid 32050368)
41. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Tomlinson GE, Chen TT, Stastny VA, Virmani AK, Spillman MA, Tonk V, Blum JL, Schneider NR, Shay JW, et al. Cancer Res 1998 58 3237 3242 9699648 (Pubitemid 28371058)
42. An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Wang XS, Prensner JR, Chen G, Cao Q, Han B, Dhanasekaran SM, Ponnala R, Cao X, Varambally S, Thomas DG, et al. Nat Biotechnol 2009 27 1005 1011 10.1038/nbt.1584 19881495
43. Detection of large-scale variation in the human genome. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, Scherer SW, Lee C, Nat Genet 2004 36 949 951 10.1038/ng1416 15286789 (Pubitemid 39167488)
44. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al. Cancer Cell 2006 10 515 527 10.1016/j.ccr.2006.10.008 17157791 (Pubitemid 44854747)
45. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. http://cgap.nci.nih.gov/Chromosomes/Mitelman
46. Chromosomal translocations in human cancer. Rabbitts TH, Nature 1994 372 143 149 10.1038/372143a0 7969446 (Pubitemid 24347832)
47. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, et al. Science 2005 310 644 648 10.1126/science.1117679 16254181 (Pubitemid 41528150)
48. Prevalence estimates of recurrent balanced cytogenetic aberrations and gene fusions in unselected patients with neoplastic disorders. Mitelman F, Mertens F, Johansson B, Genes Chromosomes Cancer 2005 43 350 366 10.1002/gcc.20212 15880352 (Pubitemid 40946470)
49. Development of personalized tumor biomarkers using massively parallel sequencing. Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, Antipova A, Lee C, McKernan K, De La Vega FM, et al. Sci Transl Med 2010 2 20ra14 10.1126/scitranslmed.3000702 20371490
50. Defining the blueprint of the cancer genome. Velculescu VE, Carcinogenesis 2008 29 1087 1091 10.1093/carcin/bgn096 18495658 (Pubitemid 351958685)
51. Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Chappuis PO, Nethercot V, Foulkes WD, Semin Surg Oncol 2000 18 287 295 10.1002/(SICI)1098-2388(200006)18:4<287::AID-SSU3>3.0.CO;2-5 10805950 (Pubitemid 30253021)
52. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA, J Natl Cancer Inst 2003 95 1482 1485 14519755 (Pubitemid 37279334)
53. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, et al. Cancer Res 2009 69 565 572 10.1158/0008-5472.CAN-08-3389 19147570
54. Synthetic lethal approaches to breast cancer therapy. Rehman FL, Lord CJ, Ashworth A, Nat Rev Clin Oncol 2010 7 718 724 10.1038/nrclinonc.2010.172 20956981
55. Network modeling links breast cancer susceptibility and centrosome dysfunction. Pujana MA, Han JD, Starita LM, Stevens KN, Tewari M, Ahn JS, Rennert G, Moreno V, Kirchhoff T, Gold B, et al. Nat Genet 2007 39 1338 1349 10.1038/ng.2007.2 17922014 (Pubitemid 350035000)
56. A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint. Wang RH, Yu H, Deng CX, Proc Natl Acad Sci USA 2004 101 17108 17113 10.1073/pnas.0407585101 15563594 (Pubitemid 39627782)
57. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Lin E, Li L, Guan Y, Soriano R, Rivers CS, Mohan S, Pandita A, Tang J, Modrusan Z, Mol Cancer Res 2009 7 1466 1476 10.1158/1541-7786.MCR-08-0522 19737969
58. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. Lee MS, Green R, Marsillac SM, Coquelle N, Williams RS, Yeung T, Foo D, Hau DD, Hui B, Monteiro AN, Glover JN, Cancer Res 2010 70 4880 4890 10.1158/0008-5472.CAN-09-4563 20516115